Syed Anjum Ali Gardezi

Syed Anjum Ali Gardezi Johns Hopkins Healthcare Aramco.

MBBS|MD | FRCP (UK) | FEBGH | FHEA
Consultant Gastroenterologist & Endoscopist
CCT (Gastroenterology, Advanced Hepatology & GIM) United Kingdom & European Board Certified.

The future of therapeutic   🔭rapidly expanding into what was once considered the exclusive domain of surgery🔪.         T...
26/06/2026

The future of therapeutic 🔭rapidly expanding into what was once considered the exclusive domain of surgery🔪.

This week, let's take a deep dive🏊‍♂️ into the fascinating world of Third Space Endoscopy where innovation, precision, and minimally invasive techniques are transforming patient care.
Turki AlAmri AbuAbdullah

Liver   vs Evidence – Are we missing the silent disease?In everyday clinical practice, we increasingly encounter patient...
27/04/2026

Liver vs Evidence – Are we missing the silent disease?

In everyday clinical practice, we increasingly encounter patients influenced by social media, -generated content, and non-medical advice. While access to information has improved, it has also led to widespread misconceptions about liver disease.

📊 our recent review published in (ClinMed), where we explore a growing challenge in modern clinical practice—misconceptions surrounding liver disease.
🔹 Normal liver enzymes ≠ normal liver
🔹 MASLD is now the leading cause of chronic liver disease globally
🔹 Significant fibrosis can exist even with normal LFTs
🔹 Non-invasive tools like FIB-4 can transform early detection in primary care
🔹 Lifestyle intervention (10–15% weight loss) remains a cornerstone of management

🚨 The real challenge?
Delayed diagnosis, under-referral, and missed opportunities for early intervention.

👉 As clinicians, we need to shift from reactive care to proactive risk stratification:

Identify high-risk patients (T2DM, obesity, metabolic syndrome)

Use simple non-invasive tools

Stratify and refer appropriately

Invest time in patient education to counter myths

💡 Liver disease remains a silent epidemic—but one we can detect earlier and manage better with the right approach.

I’ve created a visual summary of the paper for quick reference 👇

https://www.sciencedirect.com/science/article/pii/S147021182500243X?via%3Dihub

---

📍Would be interested to hear how others are addressing misinformation and delayed diagnosis in their practice.

✨ Pleased to share our latest collaborative work!🧬 Sphingosine-1-Phosphate (S1P) Receptor Modulators in Moderate–Severe ...
13/04/2026

✨ Pleased to share our latest collaborative work!

🧬 Sphingosine-1-Phosphate (S1P) Receptor Modulators in Moderate–Severe Ulcerative Colitis📊 A systematic review & meta-analysis of randomized controlled trials

🔍 Data from 8 RCTs (n=2,663 patients) to evaluate the efficacy and safety of S1P receptor modulators (including ozanimod and etrasimod) in ulcerative colitis.

📈 Key findings✅ Significant improvement in:• Clinical response• Clinical remission• Endoscopic outcomes• Histological remission• Mucosal healing

🔥 ~2x higher likelihood of response & remission

🛡️ Safety profile• Mild adverse events slightly increased• No increase in serious adverse events or discontinuation

💡 Take-home messageS1P receptor modulators represent an effective oral therapeutic option in moderate–severe UC, with robust induction outcomes and a reassuring safety profile.

🙏 Grateful to all co-authors and collaborators for their contributions to this work.

https://link.springer.com/article/10.1007/s10620-026-09887-6

Address

Cardiff

Alerts

Be the first to know and let us send you an email when Syed Anjum Ali Gardezi posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Syed Anjum Ali Gardezi:

Shortcuts

Share

Category